Bionano Genomics (BNGO) CSO reports holding 63 shares

Rhea-AI Filing Summary

Bionano Genomics, Inc. reported initial insider ownership for Chief Scientific Officer Alex Reid Hastie. The filing lists direct beneficial ownership of 63 shares of Common Stock, with no insider purchases or sales reported in this Form 3 statement.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hastie Alex Reid

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 63 shares (Direct)

Key Figures

Common Stock owned: 63.0000 shares

1 metrics

Common Stock owned 63.0000 shares Direct holdings reported for Chief Scientific Officer Alex Reid Hastie in Form 3

Key Terms

Common Stock, Chief Scientific Officer

2 terms

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Chief Scientific Officer other

""officer_title": "Chief Scientific Officer""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/30/2026 - 04:43 PM Accepted by SEC EDGAR 07/30/2026 - 04:43 PM Learn about SEC filing dates

FAQ

What did Bionano Genomics (BNGO) disclose in Alex Reid Hastie’s Form 3?

Bionano Genomics disclosed that Chief Scientific Officer Alex Reid Hastie beneficially owns 63 shares of Common Stock. These shares are reported as a direct holding, and this Form 3 does not list any insider purchase or sale transactions.

How many BNGO shares does the Chief Scientific Officer directly own?

The Chief Scientific Officer, Alex Reid Hastie, is reported as directly owning 63 shares of Bionano Genomics Common Stock. This ownership level is recorded in an initial Form 3 insider filing as a direct, rather than indirect, holding.

Does the Bionano Genomics (BNGO) Form 3 show any insider buying or selling?

No, this Form 3 for Bionano Genomics shows no insider purchases or sales. It records only a holding entry for 63 shares of Common Stock directly owned by Chief Scientific Officer Alex Reid Hastie at the time of the report.

Whose ownership is reported in the Bionano Genomics (BNGO) Form 3 filing?

The Form 3 reports the beneficial ownership of Alex Reid Hastie, Bionano Genomics’ Chief Scientific Officer. It lists his direct holding of 63 shares of Common Stock, establishing his initial reported ownership position as an executive officer.

Is the 63-share BNGO position held directly or indirectly by the insider?

The 63-share position in Bionano Genomics Common Stock is reported as held directly by Alex Reid Hastie. The filing classifies the ownership type as direct, indicating the shares are not held through an intermediary entity or account.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hastie Alex Reid

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/20/2026

3. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	63	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Jonathan V. Dixon, Attorney-in-Fact	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)